Laurion Capital Management LP Taysha Gene Therapies, Inc. Transaction History

Laurion Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.43 - $3.25 $234,888 - $533,838	164,258 New	164,258 $471,000
Q2 2023 Aug 14, 2023	SELL	$0.59 - $0.87 $71,253 - $105,068	-120,768 Reduced 9.34%	1,171,832 $773,000
Q4 2022 Feb 14, 2023	BUY	$1.39 - $2.98 $1.18 Million - $2.53 Million	850,000 Added 192.05%	1,292,600 $2.92 Million
Q2 2022 Aug 15, 2022	BUY	$2.47 - $6.77 $1.09 Million - $3 Million	442,600 New	442,600 $1.65 Million

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.